Caricamento...
Methods for Identifying Patients with Tropomyosin Receptor Kinase (TRK) Fusion Cancer
NTRK gene fusions affecting the tropomyosin receptor kinase (TRK) protein family have been found to be oncogenic drivers in a broad range of cancers. Small molecule inhibitors targeting TRK activity, such as the recently Food and Drug Administration-approved agent larotrectinib (Vitrakvi®), have sho...
Salvato in:
| Pubblicato in: | Pathol Oncol Res |
|---|---|
| Autori principali: | , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Springer Netherlands
2019
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7297824/ https://ncbi.nlm.nih.gov/pubmed/31256325 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12253-019-00685-2 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|